FDA Clears Long-Acting Aripiprazole for Schizophrenia
The US Food and Drug Administration (FDA) has approved an injectable, long-acting version of Alkermes Inc's atypical antipsychotic aripiprazole to treat adults with schizophrenia. Aripiprazole lauroxil (Aristada) is administered every 4 to 6 weeks as an injection in the arm or buttocks. The company said it expects to launch the [...]